Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearmind MedicineCMND -5.67%22 EV-to-EBITDA is 1.38 as of Sep. 01, 2026. GuruFocus rates CMND with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 402 Biotechnology companies, Clearmind Medicine ranks better than 79.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clearmind Medicine's enterprise value is $-10.79 Mil.
Clearmind Medicine's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-7.82 Mil. Therefore, Clearmind Medicine's EV-to-EBITDA for today is 1.38.
The historical rank and industry rank for Clearmind Medicine's EV-to-EBITDA or its related term are showing as below:
CMND'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.39
Current: 1.38
During the past 9 years, the highest EV-to-EBITDA of Clearmind Medicine was 1.39. The lowest was 0.00. And the median was 0.00.
CMND's EV-to-EBITDA is ranked better than 79.35% of 402
companies
in the Biotechnology industry
Industry Median: 13.8
vs CMND: 1.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Clearmind Medicine (NAS:CMND) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clearmind Medicine's PE Ratio (TTM) for today is calculated as:
Clearmind Medicine's share price for today is $1.81.
Clearmind Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-187.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Clearmind Medicine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMND vs CASIF, BIXT, ACUT: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Clearmind Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearmind Medicine EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearmind Medicine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clearmind Medicine's EV-to-EBITDA falls into.
Clearmind Medicine's current Enterprise Value is $-10.79 Mil.
Clearmind Medicine's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearmind Medicine (CMND) has a EV-to-EBITDA of 1.38 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clearmind Medicine. According to the industry distribution chart, Clearmind Medicine ranks #83 out of 402 companies in the Biotechnology industry, placing it in the top 20.6%.
Is Clearmind Medicine's EV-to-EBITDA too high?
Clearmind Medicine's current EV-to-EBITDA is 1.38. The Biotechnology industry median EV-to-EBITDA is 13.80. Clearmind Medicine's value of 1.38 is 90% below this industry median. Based on the distribution chart, Clearmind Medicine ranks #83 out of 402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's EV-to-EBITDA compare to CASIF and BIXT?
According to the Biotechnology industry distribution chart, Clearmind Medicine ranks #83 out of 402 companies for EV-to-EBITDA. This places Clearmind Medicine in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.80. Clearmind Medicine's value of 1.38 is 90% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearmind Medicine's current EV-to-EBITDA of 1.38 is 90% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clearmind Medicine. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearmind Medicine's current EV-to-EBITDA is 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (CMND) has a current EV-to-EBITDA of 1.38. The current EV-to-EBITDA is 1.38 and 90% below the Biotechnology industry median of 13.80. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Clearmind Medicine (CMND), the current EV-to-EBITDA is 1.38 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score
Get the complete analysis for CMND
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMND has been successfully added to your 
